Sep 22, 2007
| By Gayle Gerling Pettinga
| Read Time: < 1 minute
2007: The Food and Drug Administration first raised concern about incretin mimetics in 2007. They warned that incretin mimetics, especially exenatide (Byetta and Byuderon) and sitagliptin (Janumet and Januvia), could cause pancreatic diseases. The warning followed reports that a rising number of incretin mimetics users were being diagnosed with acute pancreatitis and pancreatic cancer.
Reference: “FDA Investigating Reports of Possible Increased Risk of Pancreatitis..” U.S. Food and Drug Administration, FDA, www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-investigating-reports-possible-increased-risk-pancreatitis-and-pre.
Born and raised in Evansville, Gayle is a respected, experienced lawyer and a valued community leader. She graduated near the top of her class at Indiana University’s prestigious Maurer School of Law. She’s practiced law with one of the largest firms in Indianapolis as well as one of the largest pharmaceutical companies in the world. And that means she knows how big law firms and big companies think and how they operate – and she will put that knowledge to work for you.
Gayle has received numerous awards and honors including Martindale-Hubbell — Peer Review Rated: AV®, American Institute of Personal Injury Attorneys 10 Best Attorneys in Indiana for Exceptional and Outstanding Client Service, and YWCA Evansville 100 Years, 100 Women Honoree, 2011.